Skip to main content

Advertisement

Table 2 Relationship between immune cell subset infiltration and clinicopathologic features of pure ductal carcinoma in situ

From: Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast

Clinicopathologic characteristicsCD4+ TILCD8+ TILFOXP3+ TILPD-L1+ IC
No. of TILsp valueNo. of TILsp valueNo. of TILsp valueFrequency (%)p value
Age (year) 0.577 0.218 0.815 0.792
 < 5019.7 (4.2–50.7) 12.7 (6.2–26.7) 0.0 (0.0–1.0) 21/132 (15.9) 
 ≥ 5019.0 (3.8–44.5) 12.0 (4.2–22.2) 0.0 (0.0–1.0) 13/89 (14.6) 
DCIS extent (cm) 0.950 0.799 0.811 0.929
 < 2.519.7 (5.0–47.5) 12.7 (5.3–24.2) 0.0 (0.0–1.0) 21/138 (15.2) 
 ≥ 2.517.3 (3.7–49.7) 11.3 (5.0–26.2) 0.0 (0.0–1.0) 13/83 (15.7) 
Nuclear grade < 0.001 0.001 < 0.001 < 0.001
 Low to intermediate12.7 (2.0–37.5) 10.0 (4.7–18.2) 0.0 (0.0–0.0) 11/142 (7.7) 
 High25.3 (11.5–77.8) 15.7 (8.0–35.8) 0.0 (0.0–3.0) 23/79 (29.1) 
Comedo-type necrosis 0.004 0.002 0.008 < 0.001
 Absent16.0 (3.4–42.0) 10.7 (5.3–20.1) 0.0 (0.0–0.0) 17/174 (9.8) 
 Present31.5 (13.6–86.1) 22.5 (8.5–41.5) 0.0 (0.0–5.0) 17/47 (36.2) 
ER 0.026 0.025 0.004 0.043
 Negative34.0 (13.6–82.4) 22.5 (7.6–48.8) 0.5 (0.0–5.0) 8/27 (29.6) 
 Positive17.0 (3.7–43.5) 11.8 (5.3–22.0) 0.0 (0.0–0.0) 26/194 (13.4) 
PR 0.027 < 0.001 0.002 0.019
 Negative34.0 (12.1–76.3) 24.2 (10.2–48.9) 0.0 (0.0–4.9) 11/40 (27.5) 
 Positive16.0 (3.7–42.0) 10.7 (4.7–19.5) 0.0 (0.0–0.0) 23/181 (12.7) 
HER2 0.354 0.010 0.004 0.059
 Negative17.3 (3.8–44.5) 12.0 (5.2–22.0) 0.0 (0.0–0.0) 25/189 (13.2) 
 Positive28.7 (6.8–73.2) 22.0 (7.3–48.5) 0.0 (0.0–5.2) 9/32 (28.1) 
Ki-67 index 0.001 0.009 < 0.001 < 0.001
 < 10%15.8 (3.4–40.1) 11.0 (4.9–20.2) 0.0 (0.0–0.0) 17/164 (10.4) 
 ≥ 10%34.8 (9.3–96.2) 16.2 (8.3–36.3) 0.0 (0.0–5.0) 17/57 (29.8) 
P53 0.001 0.041 0.016 0.092
 Negative16.3 (3.7–40.4) 11.5 (4.9–22.4) 0.0 (0.0–0.1) 26/192 (13.5) 
 Positive49.0 (18.8–80.8) 17.0 (9.4–31.2) 0.0 (0.0–3.0) 8/29 (27.6) 
  1. For CD4+, CD8+, and FOXP3+ TILs, p values were calculated by the Mann-Whitney U test, and data are presented as median (interquartile range)
  2. For PD-L1+ IC, p values were calculated by chi-square or Fisher’s exact test, and data are presented as frequency (%)
  3. TIL tumor-infiltrating lymphocyte, IC immune cell, DCIS ductal carcinoma in situ, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2